Common drug review new combination product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc. indication: a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults without past or present evidence of viral resistance to Doravirine, Lamivudine, or Tenofovir

Human immunodeficiency virus is responsible for causing HIV infection, a condition that gradually weakens the immune system. HIV is transmitted via body fluids such as blood, semen, genital secretions, and breast milk; most commonly from unprotected sexual intercourse or through sharing of contamina...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH June 2019, 2019
Edition:	Final (with redactions)
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK544820
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa